JP2008506690A5 - - Google Patents

Download PDF

Info

Publication number
JP2008506690A5
JP2008506690A5 JP2007521565A JP2007521565A JP2008506690A5 JP 2008506690 A5 JP2008506690 A5 JP 2008506690A5 JP 2007521565 A JP2007521565 A JP 2007521565A JP 2007521565 A JP2007521565 A JP 2007521565A JP 2008506690 A5 JP2008506690 A5 JP 2008506690A5
Authority
JP
Japan
Prior art keywords
polymorph
decitabine
cancer
endotherm
polymorph form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007521565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506690A (ja
JP5159307B2 (ja
Filing date
Publication date
Priority claimed from US10/890,828 external-priority patent/US20060014949A1/en
Application filed filed Critical
Publication of JP2008506690A publication Critical patent/JP2008506690A/ja
Publication of JP2008506690A5 publication Critical patent/JP2008506690A5/ja
Application granted granted Critical
Publication of JP5159307B2 publication Critical patent/JP5159307B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007521565A 2004-07-13 2005-07-12 デシタビンポリモルフの組成物及び処方物並びにその使用方法 Expired - Lifetime JP5159307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/890,828 2004-07-13
US10/890,828 US20060014949A1 (en) 2004-07-13 2004-07-13 Compositions and formulations of decitabine polymorphs and methods of use thereof
PCT/US2005/024676 WO2006017278A1 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2008506690A JP2008506690A (ja) 2008-03-06
JP2008506690A5 true JP2008506690A5 (cg-RX-API-DMAC7.html) 2008-09-04
JP5159307B2 JP5159307B2 (ja) 2013-03-06

Family

ID=35600347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007521565A Expired - Lifetime JP5159307B2 (ja) 2004-07-13 2005-07-12 デシタビンポリモルフの組成物及び処方物並びにその使用方法

Country Status (7)

Country Link
US (1) US20060014949A1 (cg-RX-API-DMAC7.html)
EP (1) EP1765076A4 (cg-RX-API-DMAC7.html)
JP (1) JP5159307B2 (cg-RX-API-DMAC7.html)
CN (1) CN101014246A (cg-RX-API-DMAC7.html)
AU (3) AU2005271814B2 (cg-RX-API-DMAC7.html)
CA (1) CA2573332A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006017278A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
CN101781347B (zh) * 2009-12-21 2012-09-12 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
HUE042327T2 (hu) * 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
WO2014053897A1 (en) 2012-10-01 2014-04-10 Johnson Matthey Public Limited Company Method for the purification of decitabine
CN103191144B (zh) * 2013-04-25 2014-06-18 李伟丽 一种治疗癌症的药物组合物及应用
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2020535112A (ja) 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum Midh1阻害剤とdna低メチル化剤(hma)との組合せ
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
LT4069254T (lt) 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną
AU2021260964A1 (en) 2020-04-23 2022-12-01 Pinotbio, Inc. Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
BR112023001236A2 (pt) * 2020-07-23 2023-04-04 Southern Res Inst Polimorfos de 5-aza-4'-tio-2-desoxicitidina
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (cg-RX-API-DMAC7.html) * 1963-12-22
CH527207A (de) * 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
JPS5213741B2 (cg-RX-API-DMAC7.html) * 1972-05-22 1977-04-16
JPS5527077A (en) * 1978-08-16 1980-02-26 Shin Meiwa Ind Co Ltd Solids scraper for sludge dehydrator
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract

Similar Documents

Publication Publication Date Title
JP2022520382A5 (cg-RX-API-DMAC7.html)
JP2010506932A5 (cg-RX-API-DMAC7.html)
RU2328489C3 (ru) Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения
RU2007104518A (ru) Полиморф рапамицина ii и его применение
JP2016528179A5 (cg-RX-API-DMAC7.html)
PT1612203E (pt) ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
JP2021504310A5 (cg-RX-API-DMAC7.html)
JP2007532548A5 (cg-RX-API-DMAC7.html)
JP2005520819A5 (cg-RX-API-DMAC7.html)
JP2020512315A5 (cg-RX-API-DMAC7.html)
JP2014522388A5 (cg-RX-API-DMAC7.html)
JP2020511468A5 (cg-RX-API-DMAC7.html)
RU2019112457A (ru) Несольватированный кристалл, способ его получения и его применение
JP2022534788A5 (cg-RX-API-DMAC7.html)
JP2003527319A5 (cg-RX-API-DMAC7.html)
JP2023521411A5 (cg-RX-API-DMAC7.html)
JP2015516425A5 (cg-RX-API-DMAC7.html)
JP2023524518A5 (cg-RX-API-DMAC7.html)
Borge et al. Syntheses and characterization of copper metal complexes prepared from chalcone derivatives
WO2019195569A1 (en) Solid-state forms of abemaciclib, their use and preparation
JP2020083892A5 (cg-RX-API-DMAC7.html)
JP2021533080A5 (cg-RX-API-DMAC7.html)
RU2019123279A (ru) Этан-сульфонатная соль производного хинолина
Jose et al. Influence of host preparation method on the structural phase transitions of syndiotactic polystyrene upon the guest exchange with n-alkanes
RU2006120422A (ru) Новое соединение, соответствующие композиции, способы получения и/или способы лечения